Results 191 to 200 of about 3,061,276 (249)

Development of a Japanese Sports Food Exchange List Reflecting Products Used in Japanese Athletic Settings. [PDF]

Nutrients
Isozaki M, Nakamura M, Kakutani Y.
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Association Between Dietary Advanced Glycation End Products (AGEs) and Pancreatic Fat Accumulation: Evidence From a Case-Control Study. [PDF]

Endocrinol Diabetes Metab
Shahparvari MR, Yari Z, Chegini M, Bahrizadeh M, Sadeghi A, Hekmatdoost A.   +5 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Long-term wholegrain intake in line with the Nordic Nutrition Recommendations 2023 and risk of breast cancer in a population-based cohort of women. [PDF]

Eur J Nutr
Pitt S, Håkansson N, Kaluza J, Larsson SC, Åkesson A, Wolk A.   +5 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Improving the Combustion Efficiency of Aluminum-Based Composite, Al@IL/FG, Through Surface Activation Reaction. [PDF]

Nanomaterials (Basel)
Zheng QL, Huang ZL, Xu HX, Li JZ, He W.
europepmc   +1 more source

Experiences of Persons With Disabilities Regarding Home Adaptation and Assistive Products in a Rural Community of Northern Thailand: Qualitative Study. [PDF]

Asian Pac Isl Nurs J
Kaunnil A, Apikomonkon H, Griffiths J, Munkhetvit P.   +3 more
europepmc   +1 more source

Chemicals of Concern in Chemical Hair Straightening Products: A Scoping Review. [PDF]

Curr Environ Health Rep
Weaver E, Chan M, Edwards L, Zota AR.
europepmc   +1 more source